论文部分内容阅读
目的:总结更年期心律失常患者治疗中选择倍他乐克以及普罗帕酮联合用药方案的价值。方法:随机筛选出2014年8月至2016年3月本院接受治疗的更年期心律失常患者107例,分为两组:联合用药组55例,实施倍他乐克以及普罗帕酮联合用药方案;单独用药组52例,实施倍他乐克用药方案,观察两组的疗效。结果:单独用药组有效率61.54%,联合用药组90.91%,同时联合用药组心室早搏指数改善状况优于单独用药组(P<0.05)。结论:在更年期心律失常患者治疗中,推行倍他乐克和普罗帕酮联合用药方案效果显著,有助于提升患者疗效,改善其心室早搏指数。
Objective: To summarize the value of the combination regimen of metoprolol and propafenone in the treatment of menopausal arrhythmias. Methods: A total of 107 patients with climacteric arrhythmia were randomly selected in our hospital from August 2014 to March 2016. The patients were divided into two groups: 55 in combination group, combination of metoprolol and propafenone, Fifty-two patients were treated with Betaloc to treat the two groups. Results: The effective rate was 61.54% in single drug group and 90.91% in combination group, and the improvement of ventricular premature ventricular ejection fraction in combination group was better than that in single drug group (P <0.05). Conclusion: In the treatment of climacteric patients with arrhythmia, the implementation of the combination of metoprolol and propafenone has a significant effect, which can help improve the efficacy of patients and improve their ventricular premature beats index.